Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2220 • ACR Convergence 2025
Human Milk Fatty Acid Profiles Among Breastfeeding Mothers With and Without Systemic Autoimmune Rheumatic Diseases
Rashmi Dhital¹, Kerri Bertrand², Dilli Poudel³, Christina Chambers⁴ and Monica Guma², ¹Vanderbilt University Medical Center, Brentwood, TN, ²University of California San Diego, San Diego, CA, ³Vanderbilt University Medical Center, Nashville, TN, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: Systemic autoimmune rheumatic diseases (SARDs) such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are characterized by chronic systemic inflammation and often require…
Abstract Number: 1955 • ACR Convergence 2025
Regional variations in the relationship between pericoronary fat enhancement and atherosclerosis may reflect differences in local vascular inflammation in rheumatoid arthritis
George Karpouzas¹, Frederik Enevoldsen², Dzenan Masic², Matthew Budoff¹, Ellen-Margrethe Hauge² and Sarah Ormseth³, ¹Harbor-UCLA Medical Center, Torrance, CA, ²Aarhus University, Aarhus, Denmark, ³The Lundquist Institute for Biomedical Innovation, Torrance, CA
Background/Purpose: The composition of fat around the coronary arteries is evaluated as pericoronary adipose tissue attenuation (PCATa) on coronary CT-angiogram (CCTA). In general patients PCATa…
Abstract Number: 1886 • ACR Convergence 2025
Thirty Percent of Older Adults with Rheumatic Disease Receive High-Risk Medication
Christine Anastasiou¹, Eric Roberts², gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹Stanford University, Pleasanton, CA, ²University of California, San Francisco, SF, CA, ³University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁴UCSF, San Francisco, CA
Background/Purpose: High-risk medications (HRMs) may increase the risk of adverse events such as falls and fractures, hospitalizations, hospital length of stay, and death in older…
Abstract Number: 1703 • ACR Convergence 2025
Predicting Rheumatoid Arthritis Flare Using Longitudinal Cytokine Trajectories, Machine Learning and Spatial Transcriptomic Imaging
Wittaya Suwakulsiri¹, Lukas Andriessen², Coline Fournier³, Saritha Kodikara⁴, Amy Anderson⁵, Jasmine Sim⁵, Kim-Anh Le Cao⁴, Yann Abraham⁶, Kevin Wei⁷, Kenneth Baker⁵, Arthur Pratt⁸, Mihir Wechalekar⁹, John Isaacs¹⁰ and Ranjeny Thomas¹, ¹Frazer Institute, University of Queensland, Brisbane, Queensland, Australia, ²Frazer Institute, University of Queensland, Woolloongabba, Queensland, Australia, ³Melbourne Integrative Genomics & School of Mathematics and Statistics, The University of Melbourne, Melbourne, Australia, ⁴Melbourne Integrative Genomics & School of Mathematics and Statistics, The University of Melbourne, Melbourne, Victoria, Australia, ⁵Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom, ⁶DeepLife, Vernon, France, ⁷Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁸University of Newcastle, Newcastle, United Kingdom, ⁹Flinders Medical Centre, Adelaide, Australia, ¹⁰Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Many patients living with rheumatoid arthritis (RA) can achieve remission with modern treat-to-target disease-modifying anti-rheumatic drugs (DMARDs), albeit with the risks associated with long-term…
Abstract Number: 1645 • ACR Convergence 2025
A sex-modified association between Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS) blood concentration and prevalent arthritis among young and middle-aged US adults
Queeneth Edwards¹, Samuel Mbadu¹, Jhy-Charm Soo² and Jian Zhang², ¹Georgia Southern University, Statesboro, GA, ²Georgia Southern University, statesboro
Background/Purpose: Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS) (PFAS), including Perfluorooctanoic acid (PFOA) and Perfluorooctane sulfonate (PFOS), are persistent environmental contaminants that may influence inflammatory joint diseases…
Abstract Number: 1363 • ACR Convergence 2025
Evaluation of the Clinical Outcome of Baricitinib in Patients with Rheumatoid Arthritis from Multi-center Collaborative Study in Japan: Sub-analysis for Difficult-to-treat RA.
Naoki Kondo and Nariaki Hao, Division of Orthopedic Surgery, Niigata University Medical and Dental General Hospital, Niigata, Japan
Background/Purpose: The aim is to examine the efficacy and safety of baricitinib (BARI) in Japanese rheumatoid arthritis (RA) patients in real clinical practice and is…
Abstract Number: 1346 • ACR Convergence 2025
Preliminary Result of Investigating the Response of Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) Associated SNPs: One Cohort Study
YU Chen¹, Chien-Sheng Wu², Jacob Shujui Hsu³ and Pei-Lung Chen⁴, ¹Division of Rheumatology, Allergy and Immunology, Far Eastern Memorial Hospital, New Taipei City, Taiwan, R.O.C. Graduate Institute of Medical Genomics and Proteomics, National Taiwan University, Taipei, Taiwan, R.O.C., New Taipei City, Taiwan (Republic of China), ²Division of Rheumatology, Allergy and Immunology, Far Eastern Memorial Hospital, New Taipei City, Taiwan, R.O.C., New Taipei city, Taiwan (Republic of China), ³Graduate Institute of Medical Genomics and Proteomics, National Taiwan University, Taipei, Taiwan, R.O.C., Taipei city, Taiwan (Republic of China), ⁴Graduate Institute of Medical Genomics and Proteomics, National Taiwan University, Taipei, Taiwan, R.O.C., Taipei, Taiwan (Republic of China)
Background/Purpose: Multiple Single-Nucleotide Polymorphisms (SNPs), including those in the methotrexate and azathioprine metabolic pathways, are associated with poor response to conventional disease-modifying anti-rheumatic drugs (cDMARDs)…
Abstract Number: 1328 • ACR Convergence 2025
Mortality Trends of Hypertension in Patients with Rheumatoid Arthritis in the United States (1999–2020)
Rameez Qasim¹, Khadija Mohib², Muhammad Ali³, Umm E Aimen Minhas⁴, Abu-bakr Ahmed⁵ and Areeba Minhaj⁶, ¹Allama Iqbal Medical College Lahore, Lahore, Pakistan, ²Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, ³Dow International Medical College, Karachi, Sindh, Pakistan, ⁴Allama Iqbal Medical College, Lahore, Pakistan, ⁵Kirk Kerkorian School of Medicine, Las Vegas, NV, ⁶University of South Dakota, sioux falls, SD
Background/Purpose: Hypertension is highly prevalent among patients with rheumatoid arthritis (RA) and significantly increases the risk of cardiovascular disease (CVD). Despite this established relationship, there…
Abstract Number: 1312 • ACR Convergence 2025
Evolution of patients with active rheumatoid arthritis: analysis of disease activity trajectories in a tertiary‑care rheumatology department
Elodie Portier¹, Olivier Fogel², Terkia Medkour³, Sophie Hecquet³ and Jérôme AVOUAC³, ¹Rheumatology department, Bicetre hospital, Le Kremlin Bicetre, France, ²AP-HP, Paris, France, ³Rheumatology department, Cochin hospital, Paris, France
Background/Purpose: The objective of this study was to identify clusters of patients with rheumatoid arthritis (RA) in clinical practice, according to evolution of disease activity…
Abstract Number: 1223 • ACR Convergence 2025
Pain and Fibromyalgia Across Autoimmune and Inflammatory Diseases in the AMP AIM Cohort
Alexis Ogdie¹, Astrid Rasmussen², Dana Orange³, Michelle Petri⁴, Caroline Shiboski⁵, Rebecca Haberman⁶, Mala Masson⁷, Daniel Goldman⁴, Peter Izmirly⁸, Brooke Cohen⁹, Jennifer Seifert¹⁰, Jennifer Anolik¹¹, Wade DeJager¹², Alan Baer¹³, Jill Buyon¹⁴ and Yvonne Lee¹⁵, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³The Rockefeller University, New York, NY, ⁴Johns Hopkins University School of Medicine, Timonium, MD, ⁵University of California San Francisco, San Francisco, CA, ⁶NYU Langone Health, New York, NY, ⁷NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁸New York University Grossman School of Medicine, New York, NY, ⁹Yale Physician Associate Program, New Haven, CT, ¹⁰University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ¹¹University of Rochester Medical Center, Rochester, NY, ¹²Oklahoma Medical Research Foundation, Oklahoma City, ¹³Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁴NYU Grossman School of Medicine, New York, NY, ¹⁵Northwestern University, Chicago, IL
Background/Purpose: The Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) network seeks to understand the cellular and molecular interactions that lead to inflammation and…
Abstract Number: 1049 • ACR Convergence 2025
Provider Characteristics and Beliefs and Patient Factors Associated with Long-term Glucocorticoid Use in Patients with Rheumatoid Arthritis
Michael George¹, George Reed², Kevin Kane³, Dimitrios Pappas⁴ and Joel Kremer⁵, ¹University of Pennsylvania, Philadelphia, PA, ²University of Massachusetts Chan Medical School, Worcester, MA, ³University of Massachusetts Lowell, Lowell, MA, ⁴CorEvitas, New York, NY, ⁵The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: Guidelines recommend limiting glucocorticoid (GC) use in RA, but 30% of patients continue long-term GCs. Little is known about the influence of provider attitudes…
Abstract Number: 0995 • ACR Convergence 2025
Resident Memory T Cells Stimulate Pathogenic Activity in Fibroblast-like Synoviocytes
Madison Mangin¹, Yang Yang², Yusuke Miyashita² and Margaret Chang², ¹Boston Children's Hospital, St Simons Island, GA, ²Boston Children's Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint specific memory. We previously demonstrated that joint-specific memory is mediated by CD8+ synovial resident…
Abstract Number: 0889 • ACR Convergence 2025
Potentially pathogenic memory CD4 T cells with a B cell helper phenotype expand in ACPA+ individuals during progression to rheumatoid arthritis
Ziyuan He¹, Marla Glass¹, Pravina Venkatesan², Alexandra Ferrannini³, Marie Feser⁴, Christy Bennett¹, David Boyle⁵, Kristen Demoruelle⁶, Kristine Kuhn⁷, Fan Zhang⁸, Thomas Bumol⁹, Ananda Goldrath³, Peter Skene³, V. Michael Holers¹⁰, Xiaojun Li¹, Adam Savage¹, Gary Firestein¹¹, Kevin Deane¹², Troy Torgerson¹³ and Mark Gillespie¹, ¹Allen Institute for Immunology, Seattle, WA, ²Allen Insitute, Seattle, WA, ³Allen Institute for Immunology, Seattle, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵UCSD, La Jolla, CA, ⁶University of Colorado Anschutz Medical Campus, Golden, CO, ⁷²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO, ⁸The University of Colorado, Aurora, CO, ⁹Allen Institute for Immunology, San Diego, CA, ¹⁰University of Colorado, Denver, CO, ¹¹University of California, San Diego, San Diego, CA, ¹²University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ¹³Allen Institute for Immunology, Enumclaw, WA
Background/Purpose: Prior to the onset of clinically apparent inflammatory arthritis (IA)/synovitis (clinical RA), ACPA+ ‘at-risk’ individuals (ARI) show alterations in the abundance of effector T…
Abstract Number: 0800 • ACR Convergence 2025
Microbiota-Derived Indole Promotes Collagen-Induced Arthritis Type-17 Immunity through Intestinal Dendritic Cell Cytokine Production
Jing Jing Li¹, Sucai Liu², Brenda Seymour³, Brendan Allen², Le Yiphyo², Cassandra Levens¹ and Kristine Kuhn⁴, ¹Rheumatology, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO, ³University of Colorado School of Medicine, Denver, CO, ⁴²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO
Background/Purpose: One of the most substantial impacts of microbe-host interactions at the intestinal mucosa is the development of type 17 immunity. A Th17 signature has…
Abstract Number: 0499 • ACR Convergence 2025
Olokizumab Improves Patient-Reported Outcomes in Rheumatoid Arthritis MTX-IR and TNF-IR Patients up to 106 Weeks (Results from Clinical Phase III Program)
Roy Fleischmann¹, Eugen feist² and Josef Smolen³, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ³Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria
Background/Purpose: Olokizumab (OKZ), an interleukin-6 inhibitor approved in several countries for managing rheumatoid arthritis (RA), was evaluated in previous phase III RCTs, demonstrating changes in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].